BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 35278107)

  • 1. Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancer.
    Zhang H; Liu Z; Wen H; Guo Y; Xu F; Zhu Q; Yuan W; Luo R; Lu C; Liu R; Gu J; Ge D
    Cancer Immunol Immunother; 2022 Oct; 71(10):2511-2522. PubMed ID: 35278107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 3. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation.
    Li H; Miao Y; Zhong L; Feng S; Xu Y; Tang L; Wu C; Zhang X; Gu L; Diao H; Wang H; Wen Z; Yang M
    Front Immunol; 2023; 14():1162032. PubMed ID: 37187751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TREM2
    Tan J; Fan W; Liu T; Zhu B; Liu Y; Wang S; Wu J; Liu J; Zou F; Wei J; Liu L; Zhang X; Zhuang J; Wang Y; Lin H; Huang X; Chen S; Kuang M; Li J
    J Hepatol; 2023 Jul; 79(1):126-140. PubMed ID: 36889359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
    Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
    La Fleur L; Boura VF; Alexeyenko A; Berglund A; Pontén V; Mattsson JSM; Djureinovic D; Persson J; Brunnström H; Isaksson J; Brandén E; Koyi H; Micke P; Karlsson MCI; Botling J
    Int J Cancer; 2018 Oct; 143(7):1741-1752. PubMed ID: 29667169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial interaction and functional status of CD68
    Liu X; Zhang Z; Yuan J; Yu J; Chen D
    Front Immunol; 2024; 15():1396719. PubMed ID: 38799432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choline metabolism reprogramming mediates an immunosuppressive microenvironment in non-small cell lung cancer (NSCLC) by promoting tumor-associated macrophage functional polarization and endothelial cell proliferation.
    Xiao B; Li G; Gulizeba H; Liu H; Sima X; Zhou T; Huang Y
    J Transl Med; 2024 May; 22(1):442. PubMed ID: 38730286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting TREM2 on tumor-associated macrophages enhances immunotherapy.
    Binnewies M; Pollack JL; Rudolph J; Dash S; Abushawish M; Lee T; Jahchan NS; Canaday P; Lu E; Norng M; Mankikar S; Liu VM; Du X; Chen A; Mehta R; Palmer R; Juric V; Liang L; Baker KP; Reyno L; Krummel MF; Streuli M; Sriram V
    Cell Rep; 2021 Oct; 37(3):109844. PubMed ID: 34686340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes.
    Yang Q; Zhang H; Wei T; Lin A; Sun Y; Luo P; Zhang J
    Front Immunol; 2021; 12():756722. PubMed ID: 34804043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function.
    La Fleur L; Botling J; He F; Pelicano C; Zhou C; He C; Palano G; Mezheyeuski A; Micke P; Ravetch JV; Karlsson MCI; Sarhan D
    Cancer Res; 2021 Feb; 81(4):956-967. PubMed ID: 33293426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
    Li Y; Liu H; Zhao Y; Yue D; Chen C; Li C; Zhang Z; Wang C
    Thorac Cancer; 2021 Oct; 12(20):2698-2709. PubMed ID: 34423566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.
    Martinez-Usatorre A; Kadioglu E; Boivin G; Cianciaruso C; Guichard A; Torchia B; Zangger N; Nassiri S; Keklikoglou I; Schmittnaegel M; Ries CH; Meylan E; De Palma M
    Sci Transl Med; 2021 Aug; 13(606):. PubMed ID: 34380768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Integrative Analysis Reveals the Association of
    Arora S; Singh P; Ahmad S; Ahmad T; Dohare R; Almatroodi SA; Alrumaihi F; Rahmani AH; Syed MA
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.